No Detail Found!

Efficacy and safety of empagliflozin combinations with metformin or linagliptin for Type 2 diabetes

Author(s)
Nabila Rafi Department of Pharmacology, Bahria University Medical and Dental College,Karachi,Pakistan
Muhammad Sajid Abbas Jaffri Department of Pharmacology, Bahria University Medical and Dental College,Karachi,Pakistan
Muhammad Kamran Yousuf Department of Pharmacology, Bahria University Medical and Dental College,Karachi,Pakistan
Abstract
Objective: To determine the efficacy and safety of empagliflozin in combination with metformin compared to empagliflozin in combination with linagliptin in patients with Type 2 Diabetes Mellitus (T2DM). Methodology: This analytical study was carried out at National Medical Centre (NMC) Hospital, Karachi, Pakistan, from 20 November 2022 till 20 February 2023. Two treatment groups were compared: Group A received empagliflozin 12.5 mg with metformin 500 mg OD and Group B received empagliflozin 10 mg with linagliptin 5 mg OD daily given for 12 weeks. The primary outcomes were body mass index (BMI), waist Circumference (WC), waist to hip ratio (WHR) and assessing glycated hemoglobin (HgA1c), fasting blood glucose level (FBS) and Random blood sugar (RBS). The secondary outcomes were lipid profiles, liver enzymes, pancreatic enzymes, and renal functions tests along with urinalysis. The statistical analysis was performed using SPSS 23. Result: By the end of 12th week, the difference between Group A and Group B was statistically significant with lower mean BMI, WC and WHR of Group A (p<0.05). Supplementary, glycemic control was significantly better in Group B and safety profile showed no variations between the groups. Conclusion There was a notable significant difference in body weight loss with empagliflozin-metformin combination therapy having greater effect than the empagliflozin-linagliptin combination in T2DM patients.
Publication Details
Page(s) 25-29
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 50, Issue: 1, Year: 2025

Request the full text from PASTIC

Keywords
Diabetes Mellitus, Diabetes Mellitus, Obesity, metformin, SGLT-2 inhibitors, Weight loss., DPP4 inhibitors
References
Antar SA,Ashour NA,Sharaky M,Khattab M,Ashour NA,Zaid RT .2023 .Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother, 168 : 115734.
Maric-Bilkan C .2013 .Obesity and diabetic kidney disease. Med Clin North Am, 97 : 59-74.
Than WH,Chan GC,Ng JK,C-C. JK .2020 .The role of obesity on chronic kidney disease development, progression, and cardiovascular complications. Adv Biomark Sci Technol, 2 : 24-34.
Sattar N,Presslie C,Rutter MK,McGuire DK .2024 .Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity. Diabetes Care, 47 : 531-43.
Sizar O,Podder V,Talati R.,Empagliflozin R. .2018 .. , : .
Yadav J,Ahsan F,Panda P,Mahmood T,Ansari VA,Shamim A,Empagliflozin-A Sodium Glucose A .2024 .Cotransporter-2 Inhibitor: Overview of its Chemistry, Pharmacology, and Toxicology. Curr. Diabetes Rev, 20 : 30-52.
Hedrington MS,Davis SN .2015 .The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther Clin Risk Manag, : 739-49.
Dutta S,Shah RB,Singhal S,Dutta SB,Bansal S,Sinha S .2023 .Metformin: A review of potential mechanism and therapeutic utility beyond diabetes. Drug Des Dev Ther, : 1907-32.
Hostalek U,Campbell I .2021 .Metformin for diabetes prevention: update of the evidence base. Curr Med Res Opin, 37 : 1705-17.
Goldman JD .2018 .Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy. Clin Med Insights Endocrinol Diabetes, 11 : 1-11.
Triplitt C,Solis-Herrera C,Cersosimo E,Abdul-Ghani M,Defronzo RA .2015 .Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother, 16 : 2819-33.
Leenders M,Verdijk LB,van der Hoeven L,Adam JJ,van Kranenburg J,Nilwik R .2013 .Patients With Type 2 Diabetes Show a Greater Decline in Muscle Mass, Muscle Strength, and Functional Capacity With Aging. J Am Med Dir Assoc, 14 : 585-92.
Pereira MJ,Eriksson JW .2019 .Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs, 79 : 219-30.
Cuatrecasas G,De Cabo F,Coves MJ,Patrascioiu I,Aguilar G,Cuatrecasas G .2024 .Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep, 14 : 10832.
Cho YK,Kim Y-J,Jung CH .2021 .Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. J Obes Metab Syndr, 30 : 336.
Ferreira-Hermosillo A,Molina-Ayala MA,MolinaGuerrero D,Garrido-Mendoza AP,Ramírez-Rentería C,Mendoza-Zubieta V .2020 .Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. Trials, 21 : 186-9.
Foley JE,Jordan J .2010 .Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag, 6 : 541-8.
Gilbert MP,Pratley RE .2020 .GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-tohead clinical trials. Front Endocrinol, 11 : 178-82.
Scheen AJ .2016 .DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol, 12 : 1407-17.
Min SH,Yoon J-H,Moon SJ,Hahn S,Cho YM .2018 .Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep, 8 : 4466-9.
Molina-Vega M,Muñoz-Garach A,Fernández-García JC .2018 .The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert OPion Drug Safety, 17 : 815-24.
Scheen AJ .2018 .The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf, 17 : 837-48.
Ahmed I,Raja UY,Wahab MU,Rehman T,Ishtiaq O,Aamir AH .2022 .Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study. BMC Endocr Disord, 22 : 247.
Hadjadj S,Rosenstock J,Meinicke T,Woerle HJ,Broedl UC .2016 .Initial Combination of Empagliflozin and Metformin in Patients with Type 2 Diabetes. Diabetes Care, 39 : 1718-28.
0

Citations

0

Downloads

79

Views